Literature DB >> 15105181

Limitations of the odds ratio in gauging the performance of a diagnostic, prognostic, or screening marker.

Margaret Sullivan Pepe1, Holly Janes, Gary Longton, Wendy Leisenring, Polly Newcomb.   

Abstract

A marker strongly associated with outcome (or disease) is often assumed to be effective for classifying persons according to their current or future outcome. However, for this assumption to be true, the associated odds ratio must be of a magnitude rarely seen in epidemiologic studies. In this paper, an illustration of the relation between odds ratios and receiver operating characteristic curves shows, for example, that a marker with an odds ratio of as high as 3 is in fact a very poor classification tool. If a marker identifies 10% of controls as positive (false positives) and has an odds ratio of 3, then it will correctly identify only 25% of cases as positive (true positives). The authors illustrate that a single measure of association such as an odds ratio does not meaningfully describe a marker's ability to classify subjects. Appropriate statistical methods for assessing and reporting the classification power of a marker are described. In addition, the serious pitfalls of using more traditional methods based on parameters in logistic regression models are illustrated.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15105181     DOI: 10.1093/aje/kwh101

Source DB:  PubMed          Journal:  Am J Epidemiol        ISSN: 0002-9262            Impact factor:   4.897


  435 in total

1.  Sufficient dimension reduction for longitudinally measured predictors.

Authors:  Ruth M Pfeiffer; Liliana Forzani; Efstathia Bura
Journal:  Stat Med       Date:  2011-12-09       Impact factor: 2.373

2.  Novel metrics for evaluating improvement in discrimination: net reclassification and integrated discrimination improvement for normal variables and nested models.

Authors:  Michael J Pencina; Ralph B D'Agostino; Olga V Demler
Journal:  Stat Med       Date:  2011-12-07       Impact factor: 2.373

3.  Reporting recommendations for tumor marker prognostic studies (REMARK): explanation and elaboration.

Authors:  Douglas G Altman; Lisa M McShane; Willi Sauerbrei; Sheila E Taube
Journal:  BMC Med       Date:  2012-05-29       Impact factor: 8.775

4.  Reporting Recommendations for Tumor Marker Prognostic Studies (REMARK): explanation and elaboration.

Authors:  Douglas G Altman; Lisa M McShane; Willi Sauerbrei; Sheila E Taube
Journal:  PLoS Med       Date:  2012-05-29       Impact factor: 11.069

Review 5.  Personalized medicine: hope or hype?

Authors:  Keyan Salari; Hugh Watkins; Euan A Ashley
Journal:  Eur Heart J       Date:  2012-06-01       Impact factor: 29.983

6.  Challenges in Predicting Recurrence After Resection of Node-Negative Non-Small Cell Lung Cancer.

Authors:  Lucas W Thornblade; Michael S Mulligan; Katherine Odem-Davis; Billanna Hwang; Rachel L Waworuntu; Erika M Wolff; Larry Kessler; Douglas E Wood; Farhood Farjah
Journal:  Ann Thorac Surg       Date:  2018-07-19       Impact factor: 4.330

7.  A unified inference procedure for a class of measures to assess improvement in risk prediction systems with survival data.

Authors:  Hajime Uno; Lu Tian; Tianxi Cai; Isaac S Kohane; L J Wei
Journal:  Stat Med       Date:  2012-10-05       Impact factor: 2.373

Review 8.  Genetic profiling and individualized assessment of fracture risk.

Authors:  Tuan V Nguyen; John A Eisman
Journal:  Nat Rev Endocrinol       Date:  2013-02-05       Impact factor: 43.330

9.  The Best Predictors of Survival: Do They Vary by Age, Sex, and Race?

Authors:  Noreen Goldman; Dana A Glei; Maxine Weinstein
Journal:  Popul Dev Rev       Date:  2017-07-17

10.  Association of Malnutrition-Inflammation Score with quality of life and mortality in hemodialysis patients: a 5-year prospective cohort study.

Authors:  Mehdi Rambod; Rachelle Bross; Jennifer Zitterkoph; Deborah Benner; Juhi Pithia; Sara Colman; Csaba P Kovesdy; Joel D Kopple; Kamyar Kalantar-Zadeh
Journal:  Am J Kidney Dis       Date:  2008-12-13       Impact factor: 8.860

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.